0001564590-22-020817.txt : 20220520 0001564590-22-020817.hdr.sgml : 20220520 20220520093830 ACCESSION NUMBER: 0001564590-22-020817 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220519 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220520 DATE AS OF CHANGE: 20220520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evoke Pharma Inc CENTRAL INDEX KEY: 0001403708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208447886 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36075 FILM NUMBER: 22945774 BUSINESS ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 BUSINESS PHONE: 858-345-1494 MAIL ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 8-K 1 evok-8k_20220519.htm 8-K evok-8k_20220519.htm
false 0001403708 --12-31 0001403708 2022-05-19 2022-05-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  May 19, 2022

 

EVOKE PHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

001-36075

 

20-8447886

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

420 Stevens Avenue, Suite 370

Solana Beach, California

 

92075

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (858) 345-1494

(Former Name or Former Address, if Changed Since Last Report.)

 

Securities registered pursuant to Section 12(b) of the Exchange Act

 

 

 

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock,
par value $0.0001 per share

EVOK

The Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 


 

Item 3.03Material Modification to Rights of Security Holders.

 

The information contained in Item 5.03 below is incorporated by reference into this Item 3.03.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On May 19, 2022, Evoke Pharma, Inc. (the “Company”) filed an amendment (the “Amendment”) to its amended and restated certificate of incorporation to effectuate a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). Pursuant to the Amendment, at the effective time of 5:00 p.m. Eastern Time on May 20, 2022, each twelve (12) shares of Common Stock issued and outstanding will be combined into one (1) validly issued, fully paid and non-assessable share of Common Stock (the “Reverse Stock Split”). The par value per share remains the same. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of Common Stock are instead entitled to receive a proportional cash payment. The Reverse Stock Split will not reduce the total number of shares of Common Stock that the Company is authorized to issue, which will remain 50,000,000 shares.  Trading of the Common Stock on a Reverse Stock Split-adjusted basis will begin at the opening of trading on the Nasdaq Capital Market on May 23, 2022.  The new CUSIP number for the Common Stock following the Reverse Stock Split is 30049G 203.

 

In addition, proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of Common Stock and the number of shares of Common Stock reserved for issuance pursuant to the Company’s equity incentive compensation plans.

 

The Reverse Stock Split ratio was selected pursuant to the authority granted to the board of directors of the Company by stockholders at the Annual Meeting of Stockholders held on April 27, 2022. A copy of the Amendment filed with the Secretary of State of the State of Delaware is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

 

 

 

Exhibit No.

  

Description

 

 

3.1

  

Certificate of Amendment to Amended and Restated Certificate of Incorporation of Evoke Pharma, Inc.

 

 

104

  

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

EVOKE PHARMA, INC.

 

 

 

 

Date: May 20, 2022

 

 

 

By:

 

/s/ Matthew J. D’Onofrio

 

 

 

 

Name:

 

Matthew J. D’Onofrio

 

 

 

 

Title:

 

Executive Vice President,
Chief Business Officer and Secretary

 

 

EX-3.1 2 evok-ex31_6.htm EX-3.1 evok-ex31_6.htm

Exhibit 3.1

CERTIFICATE OF AMENDMENT

 

OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

 

OF EVOKE PHARMA, INC.

 

Evoke Pharma, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify:

 

 

1.

The name of the Corporation is Evoke Pharma, Inc. The original Certificate of Incorporation of Evoke Pharma, Inc. was filed with the Secretary of State of Delaware on January 29, 2007.

 

 

2.

Upon the filing and effectiveness (the “Effective Time”) pursuant to the DGCL of this Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Corporation, as amended, each twelve shares of the Corporation’s common stock, par value $0.0001 per share, issued and outstanding immediately prior to the Effective Time (the “Old Shares”) shall automatically be combined into one validly issued, fully paid and non-assessable share of common stock without any further action by the Corporation or the holder thereof, subject to the treatment of fractional share interests as described below (the “Reverse Stock Split”). The Corporation shall not issue fractional shares in connection with the Reverse Stock Split. Holders of Old Shares who would otherwise be entitled to receive a fraction of a share on account of the Reverse Stock Split shall receive, upon surrender of the stock certificates formerly representing the Old Shares, in lieu of such fractional share, an amount in cash equal to the product of (1) the closing sale price per share of the common stock as reported by The Nasdaq Capital Market on the last trading day preceding the Effective Time by (2) the number of Old Shares held by such holder that would otherwise have been exchanged for such fractional share interests.

 

 

3.

This Certificate of Amendment shall become effective as of May 20, 2022 at 5:00 p.m. Eastern time.  

 

 

4.

This Certificate of Amendment was duly adopted in accordance with Section 242 of the DGCL. The Board of Directors of the Corporation duly adopted resolutions setting forth and declaring advisable this Certificate of Amendment and directed that such amendment be considered by the stockholders of the Corporation. An annual meeting of stockholders was duly called upon notice in accordance with Section 222 of the DGCL and held on April 27, 2022, at which meeting the necessary number of shares were voted in favor of such amendment. The stockholders of the Corporation duly adopted this Certificate of Amendment.

 

IN WITNESS WHEREOF, this Certificate of Amendment of Amended and Restated Certificate of Incorporation has been executed as of this 19th day of May, 2022.

 

EVOKE PHARMA, INC.

 

 

By:  /s/ David A. Gonyer, R.Ph.

Name:  David A. Gonyer, R.Ph.

Title: President and Chief Executive Officer

 

 

 

 

 

 

 

EX-101.SCH 3 evok-20220519.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 evok-20220519_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Current Fiscal Year End Date Current Fiscal Year End Date EX-101.PRE 5 evok-20220519_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 19, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 19, 2022
Entity Registrant Name EVOKE PHARMA, INC.
Entity Central Index Key 0001403708
Entity Emerging Growth Company false
Entity File Number 001-36075
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-8447886
Entity Address, Address Line One 420 Stevens Avenue
Entity Address, Address Line Two Suite 370
Entity Address, City or Town Solana Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92075
City Area Code (858)
Local Phone Number 345-1494
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock,par value $0.0001 per share
Trading Symbol EVOK
Security Exchange Name NASDAQ
Current Fiscal Year End Date --12-31
XML 7 evok-8k_20220519_htm.xml IDEA: XBRL DOCUMENT 0001403708 2022-05-19 2022-05-19 false 0001403708 --12-31 8-K 2022-05-19 EVOKE PHARMA, INC. DE 001-36075 20-8447886 420 Stevens Avenue Suite 370 Solana Beach CA 92075 (858) 345-1494 Common Stock,par value $0.0001 per share EVOK NASDAQ false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,Y,M%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #.3+1446^%W.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*''H&";UI:.G#@8K;.QF;+4UBQUC:R1]^R5>FS*V!]C1TN]/ MGT"M#D+W$9]C'S"2Q70WNLXGH<.:G8B" $CZA$ZE,1@M(? MZHC J^H>')(RBA3,P"(L1"9;HX6.J*B/%[S1"SY\QB[#C ;LT*&G!'59 Y/S MQ' >NQ9N@!E&&%WZ+J!9B+GZ)S9W@%V28[)+:AB&GW4M>M[ ^ MD?(:IU_)"CH'7+/KY-=F\[C?,LDKSHMJ5?!J7S>B>1!\]3Z[_O"[";O>V(/] MQ\970=G"K[N07U!+ P04 " #.3+14F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ,Y,M%3=BU(:= 0 (<1 8 >&PO=V]R:W-H965T&UL MC9A=<^(V%(:OM[]"P_1B=P9B6YB/[!!F')+L,MDD--#=:3N]$+8 36S+E>00 M_GV/#+'IUAQS S;XO#PZ.GJ/Q&@KU8O><&[(6Q*G^JJU,2;[[#@ZW/"$Z0N9 M\12^64F5, .W:NWH3'$6%4%)[%#7[3L)$VEK/"H^FZGQ2.8F%BF?*:+S)&%J M=\UCN;UJ>:WW#Y[%>F/L!\YXE+$UGW/S>S93<.>4*I%(>*J%3(GBJZM6X'V^ MIGT;4#SQ7?"M/KHF=BA+*5_LS32Z:KF6B,<\-%:"P=LKG_ XMDK \<]!M%7^ MI@T\OGY7ORL&#X-9,LTG,OXA(K.Y:@U;).(KEL?F66Z_\L. >E8OE+$N7LEV M_ZSOMTB8:R.30S 0)"+=O[.W0R*. [P3 ?000 ON_0\5E#?,L/%(R2U1]FE0 MLQ?%4(MH@!.IG96Y4?"M@#@SOI%A#DDVA*41N4V-,#LR3?>S#5D;.09^Q#[J MA ?!Z[T@/2'XP';$NVP3ZE+ZWV@'T$H^6O+10JY[0FXB7[DB?P5+;13,X-^( M9+>4[!:2?M.0%[N,UPT0#Q]V[A$(OX3P494 "**"XBYFZSH*/'[%8LT1CE[) MT3LO&3.NA+0E$!$HI-J\X$J'B?_EPX>&J>^7:'U4\%"-SWPM[.0#XR-+:L$: M=+X_W=^2V=?@^2%HD^GCY *!&Y1P@W/@)I ZQ6)8,A%_(_=\5X>'*[FNZ_EN M=^ .$:QAB34\!^LVX6HMTC7Y O%F0R8RR5A:"X?K-97990[7G8@Y><03=-0JDRJPNW:9&Z@]HE4D+$<9A8F6$:U M)=>@?G.+01Z9LW<.Y(*]D6D$I296(BQ(D20V2%*W,_3]P7#8QP@K>_;H.81! M%"FN=?O]@GR#Y\A36I\[7-*G+LP#?X763P)XS;$"]"K7]W#?1DD76UE+BDO. M1AO5SC6M. @RMZA3>6:VB1)M);<"5_Q39Z06,*U[2!J.I&H6'^WLQ MC0'LF$^CX (?A[WA)PRE:@X>[N;?9 A9F6UDBKEP@TC7[W4\_]+'B*JVX.&> M_D,)8WAJ&U22IP=ST[54N%!3HZ)58Z"X=<.Z$:$PMGL^0($KP>(ZG@:51IZJ M!U#*=T)(#X<5MM^VPLX1]L1/JU7]_#7H-9(=;?R)R'.=1;[3:H0XLX\R94JSDU"6S?[@\-L8*>6!KE.QZ.= MKE>'YAP=J^U?% _,;JHUB?D*I-R+ 8Q9[4_]^QLCL^*DO90&SNW%Y88S6 OV M ?A^):5YO[&']_*_E_&_4$L#!!0 ( ,Y,M%2?H!OPL0( .(, - M>&PO9KEMWDOSAR+DCO9*ZW="C<\W[ M)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3 M;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@ M:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_& M%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V M_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUS MS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D M^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>P MSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0 M_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^& M<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8 M[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( ,Y,M%27BKL< MP !," + 7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$ M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8E MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:GH_ 0 / ( \ !X;"]W;W)K8F]O:RYX;6R-49:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+ MD6M#V743&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+ M)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\ M@2P/73>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0 M ( ,Y,M%0D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&R MGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0 MDBBZ0=@S9)[NF:*'3^ 5!+ M P04 " #.3+1499!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX M;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85- MK'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+ MY8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE# MVQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/) MW55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_ ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( ,Y,M%0'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ SDRT M5%%OA=SN *P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ SDRT5)E&PO=V]R:W-H965T&UL4$L! A0#% @ SDRT5)^@&_"Q @ X@P T ( ! MMPP 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL M4$L! A0#% @ SDRT5"0>FZ*M ^ $ !H ( !Z!$ M 'AL+U]R96QS+W=O9(9 0 SP, !, ( !S1( %M#;VYT96YT7U1Y<&5S72YX 8;6Q02P4& D "0 ^ @ %Q0 end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports evok-8k_20220519.htm evok-20220519.xsd evok-20220519_lab.xml evok-20220519_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "evok-8k_20220519.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "evok-8k_20220519.htm" ] }, "labelLink": { "local": [ "evok-20220519_lab.xml" ] }, "presentationLink": { "local": [ "evok-20220519_pre.xml" ] }, "schema": { "local": [ "evok-20220519.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "evok", "nsuri": "http://www.evokepharma.com/20220519", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "evok-8k_20220519.htm", "contextRef": "C_0001403708_20220519_20220519", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "evok-8k_20220519.htm", "contextRef": "C_0001403708_20220519_20220519", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220519/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001564590-22-020817-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-020817-xbrl.zip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